Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.38 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.38 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9307 | 1.00 | ACE (0.43) | ACEALDH1A1SMN1; SMN2EPHX1CA12 | |
| SCHEMBL17628753 | 1.00 | ACE (0.43) | ACEALDH1A1SMN1; SMN2EPHX1CA12 | |
| SCHEMBL1188709 | 0.97 | EPHX1 (0.44) | ACEALDH1A1SMN1; SMN2EPHX1CA12 | |
| SCHEMBL11922662 | 0.97 | EPHX1 (0.44) | ACEALDH1A1SMN1; SMN2EPHX1CA12 | |
| SCHEMBL31323959 | 0.97 | EPHX1 (0.44) | ACEALDH1A1SMN1; SMN2EPHX1CA12 | |
| SCHEMBL1595664 | 0.97 | EPHX1 (0.44) | ACEALDH1A1SMN1; SMN2EPHX1CA12 | |
| Cyclohexane SCHEMBL18344237 | 0.97 | EPHX1 (0.44) | ACEALDH1A1SMN1; SMN2EPHX1CA12 | |
| SCHEMBL2055541 | 0.97 | EPHX1 (0.44) | ACEALDH1A1SMN1; SMN2EPHX1CA12 | |
| SCHEMBL29234882 | 0.97 | ACE (0.42) | ACEALDH1A1SMN1; SMN2EPHX1CA12 | |
| Hydrochloric Acid SCHEMBL5741895 | 0.97 | ACE (0.42) | ACEALDH1A1SMN1; SMN2EPHX1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10426135-B2 | Methyl- and trifluromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof | PFIZER INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-10385036-B2 | Sulfonamide-substituted indole modulators of RORC2 and methods of use thereof | PFIZER INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-10336748-B2 | Methyoxy-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof | PFIZER INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20190150401-A1 | Methyl- and Trifluromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof | PFIZER INC. (US) | 2019-05-23 | — | — | US | disclosed |
| US-10227346-B2 | Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use therof | PFIZER INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180273504-A1 | Sulfonamide-Substituted Indole Modulators of RORC2 and Methods of Use Thereof | PFIZER INC. (US) | 2018-09-27 | — | — | US | disclosed |
| US-20180170928-A1 | Methyl- and Trifluoromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof | PFIZER INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-9920054-B2 | Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof | PFIZER INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20180002330-A1 | Methyoxy-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof | PFIZER INC. (US) | 2018-01-04 | — | — | US | disclosed |
| EP-3250561-A1 | SULFONAMIDE-SUBSITUTED INDOLE MODULATORS OF RORC2 AND METHODS OF USE THEREOF | Pfizer Inc (US) | 2017-12-06 | — | — | EP | disclosed |
| US-8529882-B2 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-10 | — | — | US | disclosed |
| US-20120282219-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120252734-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES | OLSON GARY LEE (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120064034-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110217324-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES AND METHODS OF USE THEREOF | PROVID PHARMACEUTICALS, INC. | 2011-09-08 | — | — | US | disclosed |
| US-7425576-B2 | Compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2008-09-16 | — | — | US | disclosed |
| US-20070142300-A1 | Novel compounds as inhibitors of hepatitis C virus NS3 serine protease | MERCK SHARP & DOHME LLC | 2007-06-21 | — | — | US | disclosed |
| US-7186747-B2 | Compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1734962-A2 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PainCeptor Pharma Corp. (CA) | 2006-12-27 | — | — | EP | disclosed |
| WO-2006038070-A2 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002330-A1 | Methyoxy-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof | RORC, RORB, RORA | ACE 2950/4885ALDH1A1 484/4885SMN1; SMN2 3331/4885 |
| US-20070142300-A1 | Novel compounds as inhibitors of hepatitis C virus NS3 serine protease | SERPINB1, HAVCR2, HPN | ACE 20/4885ALDH1A1 1238/4885SMN1; SMN2 3491/4885 |
| US-20110217324-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES AND METHODS OF USE THEREOF | HLA-DRB1, CD74, MICA | ACE 718/4885ALDH1A1 2379/4885SMN1; SMN2 3457/4885 |
| US-10227346-B2 | Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use therof | RORC, RORB, RORA | ACE 3488/4885ALDH1A1 1091/4885SMN1; SMN2 2963/4885 |
| US-20180170928-A1 | Methyl- and Trifluoromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof | RORC, RORB, RORA | ACE 3808/4885ALDH1A1 715/4885SMN1; SMN2 3039/4885 |
| US-10336748-B2 | Methyoxy-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof | RORC, RORB, RORA | ACE 2950/4885ALDH1A1 484/4885SMN1; SMN2 3331/4885 |
| US-20180273504-A1 | Sulfonamide-Substituted Indole Modulators of RORC2 and Methods of Use Thereof | RORC, RORB, RORA | ACE 3722/4885ALDH1A1 491/4885SMN1; SMN2 4056/4885 |
| US-20120252734-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES | HLA-DRB1, CD74, MICA | ACE 263/4885ALDH1A1 2074/4885SMN1; SMN2 3602/4885 |
| US-20120064034-A1 | Peptidomimetic protease inhibitors | CTSC, PREP, PEPD | ACE 109/4885ALDH1A1 2218/4885SMN1; SMN2 4224/4885 |
| US-20120282219-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | CTSC, PEPD, PREP | ACE 58/4885ALDH1A1 2639/4885SMN1; SMN2 4184/4885 |
| US-10385036-B2 | Sulfonamide-substituted indole modulators of RORC2 and methods of use thereof | RORC, RORB, RORA | ACE 4166/4885ALDH1A1 446/4885SMN1; SMN2 3701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.